Latest Breaking News On - செயல்படுத்தல் வழிகாட்டல் - Page 1 : comparemela.com
DPH Issues New Implementation Guidance Regarding Governor Lamont s COVID-19 Vaccine Mandate - Coronavirus (COVID-19)
mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
NRC Solicits Comments on Environmental Justice | Hogan Lovells
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression
Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants
TORONTO, June 9, 2021 /PRNewswire/ - Braxia Scientific Corp. ( Braxia , or the Company ), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the Guidelines ) for the clinical use of rapi
Braxia Scientific team-led guidelines into clinical uses of ketamine and esketamine published in prestigious American Journal of Psychiatry
Its CEO Roger McIntyre and medical director Joshua Rosenblat led a team of experts to develop the International Expert Opinion and Implementation Guidance for the clinical use of rapid-acting ketamine and esketamine for treatment-resistant depression Esketamine therapy received FDA approval with breakthrough status in 2019
Braxia Scientific Corp (CSE:BRAX) (OTCMKTS:BRAXF) (FRA:496) CEO Roger McIntyre saw his research into the clinical uses of ketamine and esketamine published in the prestigious American Journal of Psychiatry.
McIntyre and Braxia’s medical director Joshua Rosenblat led a team of 26 experts to develop the International Expert Opinion and Implementation Guidance (Guidelines) for the clinical use of rapid-acting Ketamine and Esketamine for treatment-resistant depression, according to Braxia.